The pharmaceuticals group Novartis has announced it will join forces with Synthetic Genomics Vaccines to develop flu vaccines using “revolutionary” technology.
This content was published on
1 minute
swissinfo.ch and agencies
Basel-based Novartis said its collaboration with the United States group was aimed at accelerating the production of flu strains required for vaccine manufacturing.
A statement on Thursday said that the three-year agreement could ultimately lead to a more effective response to seasonal and pandemic flu outbreaks.
Novartis and other vaccines companies currently rely on the World Health Organization to identify and distribute live reference viruses to create seasonal and pandemic viruses.
Under the terms of the accord, Novartis and its partner will develop a “bank” of synthetically constructed seed viruses ready to go into production as soon as the WHO identifies the flu strains.
The technology could reduce the vaccine production time by up to two months, which is particularly critical in the event of a pandemic, Novartis said.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Novartis found guilty of sex discrimination
This content was published on
At the end of a six-week trial on Monday it awarded compensatory damages of $3.3 million (SFr3.74 million) to 12 women, and punitive damages to a larger group. The class action lawsuit – representing 5,600 women – alleged that the women were discriminated against in the areas of pay, promotions, and pregnancy-related matters. They are…
This content was published on
The announcement on Tuesday came as the Basel-based group reported record results in 2009. It posted a profit of $8.4 billion (SFr8.7 billion), up four per cent compared with last year. Novartis also reported that the board of directors had appointed the head of its global pharmaceuticals division, Joe Jimenez, to succeed Vasella, who will…
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.